News

Novartis has reported results from phase III trial showing QAB149 (indacaterol) significantly improves lung function and provides reduction in breathlessness compared to tiotropium, a current treatment option. QAB149

Wyeth Pharmaceuticals has reported the findings from a placebo-controlled phase 3 study of bazedoxifene 20mg extended to five years, which indicated a significant reduction versus placebo in new

HUYA Bioscience International has entered into a strategic partnership agreement with Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (GIBH). The agreement with GIBH is expected

Bavarian Nordic has signed a contract with the military of an undisclosed EU country for the delivery of a small order for Imvamune. The vaccines will be delivered

Merck Sharp & Dohme (MSD) has reported that Isentress (raltegravir) has been granted an expanded license from the European Union Commission for use in combination with other antiretroviral

Phosphagenics has reported successful completion of a phase 1 clinical study of its patented oxycodone transdermal matrix patch system. The results of the trial established that after a

NiKem Research has received, from the Italian Ministry of Health, GLP certification of its bioanalysis facilities to further extend its drug discovery service capabilities. With this certification NiKem

Basilea Pharmaceutica’s (Basilea) anti-infective compounds ceftobiprole, isavuconazole and the novel antibiotic BAL30072’s data were presented at the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San

The FDA has approved Sanofi Pasteur’s supplemental biologics license application (sBLA) for licensure of its Influenza A (H1N1) 2009 Monovalent Vaccine. Monovalent Vaccine is an inactivated influenza virus